33 related articles for article (PubMed ID: 8899474)
1. Inhibitory effects of
Sadeghimanesh A; Gholipour S; Torki A; Amini-Khoei H; Lorigooini Z; Habtemariam S
Biomedicine (Taipei); 2021; 11(1):19-25. PubMed ID: 35223391
[TBL] [Abstract][Full Text] [Related]
2. [Vitaprost Forte in the treament of patients with benign prostatic hyperplasia: pathogenetic basics and clinical results].
Kuzmin IV
Urologiia; 2019 Sep; (4):141-147. PubMed ID: 31535821
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of testicular delta 5-3 beta-hydroxysteroid dehydrogenase and prostatic 5 alpha-reductase activities in rats and humans by strogen forte extract.
Tóth I; Szécsi M; Julesz J; Faredin I; Behnke B
Int Urol Nephrol; 1996; 28(3):337-48. PubMed ID: 8899474
[TBL] [Abstract][Full Text] [Related]
4. Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo.
Weisser H; Behnke B; Helpap B; Bach D; Krieg M
Eur Urol; 1997; 31(1):97-101. PubMed ID: 9032543
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs.
Ayub M; Levell MJ
J Steroid Biochem; 1987 Nov; 28(5):521-31. PubMed ID: 2824931
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 3 alpha-hydroxysteroid oxidoreductase and 5 alpha-reductase activity by antiandrogens and indomethacin in the rat prostate.
Fukabori Y; Takezawa Y; Yamanaka H; Honma S
Prostate; 1992; 21(4):255-67. PubMed ID: 1281319
[TBL] [Abstract][Full Text] [Related]
7. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia.
Kondás J; Philipp V; Diószeghy G
Int Urol Nephrol; 1996; 28(6):767-72. PubMed ID: 9089044
[TBL] [Abstract][Full Text] [Related]
8. Protein measurement with the Folin phenol reagent.
LOWRY OH; ROSEBROUGH NJ; FARR AL; RANDALL RJ
J Biol Chem; 1951 Nov; 193(1):265-75. PubMed ID: 14907713
[No Abstract] [Full Text] [Related]
9. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
[TBL] [Abstract][Full Text] [Related]
10. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year.
Romics I; Schmitz H; Frang D
Int Urol Nephrol; 1993; 25(6):565-9. PubMed ID: 7513678
[TBL] [Abstract][Full Text] [Related]
11. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia.
Champault G; Patel JC; Bonnard AM
Br J Clin Pharmacol; 1984 Sep; 18(3):461-2. PubMed ID: 6207850
[No Abstract] [Full Text] [Related]
12. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate.
Carilla E; Briley M; Fauran F; Sultan C; Duvilliers C
J Steroid Biochem; 1984 Jan; 20(1):521-3. PubMed ID: 6200701
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
